---
schema_version: "secwatch.filing_event.v1"
accession: "0001551306-23-000060"
form_type: "8-K"
ticker: "PGNY"
cik: "0001551306"
company_name: "Progyny, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:09:15.571051+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Progyny Q2 revenue $279.4M (+43% YoY); raises full-year guidance

## Summary
- Revenue $279.4M (+43% YoY); net income $15.0M ($0.15 diluted EPS) vs $8.8M ($0.09) YoY.
- Adjusted EBITDA $47.5M (+44% YoY); record operating cash flow $76.0M, helped by new pharmacy partner agreements.
- Clients grew to 384 (from 273); ART cycles 14,771 (+42% YoY); utilization rates improved.
- FY 2023 revenue guidance raised to $1,075-1,090M (37-39% growth); adj EBITDA guided $183-187.5M.
- Q3 2023 revenue guided $268-273M; adj EBITDA $44.7-46.2M.

## SEC filing metadata
- accession: 0001551306-23-000060
- form_type: 8-K
- ticker: PGNY
- cik: 0001551306
- company_name: Progyny, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/0001551306-23-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/pgny-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551306-23-000060
- JSON: https://secwatch.observer/filing/0001551306-23-000060.json
- Plain text: https://secwatch.observer/filing/0001551306-23-000060.txt

## Key facts
- Earnings Releases
  Progyny, Inc. reported three-month period ended June 30, 2023 results: revenue $279,373, net income $14,991, EPS $0.15. Guidance raised.
  - Period: three-month period ended June 30, 2023
  - Revenue: $279,373
  - Net income: $14,991
  - EPS: $0.15
  - Guidance: raised
  - Result: reported results
  source text: quarter,” said Mark Livingston, Progyny’s Chief Financial Officer. Second Quarter 2023 Highlights: (unaudited; in thousands, except per share amounts) 2Q 2023 2Q 2022 Revenue $279,373 $195,004 Gross Profit $60,641 $43,887 Gross Margin 21.7% 22.5% Net Income $14,991 $8,768 Net Income per Diluted Share 1 $0.15 $0.09 Adjusted EBITDA 2 $47,464 $32,878 Adjusted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/0001551306-23-000060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.